NLS Pharmaceutics to Participate in Upcoming Investor Conferences
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) announces its participation in key upcoming investor conferences. CEO Alex Zwyer will provide a company update at the 2023 BIO CEO & Investor Conference on March 12-14, 2023, and will be available for one-on-one meetings. Additionally, he will participate in the 35th Annual Roth Conference during the same dates. NLS focuses on developing innovative therapies for rare and complex central nervous system disorders.
- None.
- None.
Insights
Analyzing...
ZURICH, SWITZERLAND / ACCESSWIRE / January 11, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, is pleased to announce its participation in the following upcoming conferences:
- 2023 BIO CEO & Investor Conference
Alex Zwyer, NLS' Chief Executive Officer, will present a company update at the 2023 BIO CEO & Investor Conference on March 12-14, 2023, and will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering™ system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering
- 35th Annual Roth Conference
Alex Zwyer, NLS' Chief Executive Officer, will participate in and host investor meetings at the 35th Annual Roth Conference on March 12-14, 2023.If you plan on attending the conference, please reach out to your ROTH representative to request a meeting.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/734815/NLS-Pharmaceutics-to-Participate-in-Upcoming-Investor-Conferences
FAQ
What conferences is NLS Pharmaceutics participating in 2023?
Who is the CEO of NLS Pharmaceutics?
How can I schedule a meeting with NLS Pharmaceutics at the conferences?
What is the focus of NLS Pharmaceutics?
What are the stock symbols for NLS Pharmaceutics?
